Research programme: phytocannabinoid based therapeutics - Biopharmaceutical Research Company
Latest Information Update: 28 Feb 2025
At a glance
- Originator Biopharmaceutical Research Company
- Class Cannabinoids; Cyclohexenes; Hydroxybenzoic acids; Salicylic acids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Movement disorders; Sleep disorders
Most Recent Events
- 27 Dec 2024 Preclinical trials in Movement disorders in USA (unspecified route) (Biopharmaceutical Research Company pipeline, December 2024)
- 27 Dec 2024 Preclinical trials in Sleep disorders in USA (unspecified route) (Biopharmaceutical Research Company pipeline, December 2024)